Eligibility requirements for the GLP-1 Bridge Program include: Age 18 or older Enrollment in a Medicare Part D or Medicare Advantage Prescription Drug (MA-PD) plan One of the following BMI and health condition combinations: BMI 35 (regardless of other health conditions) BMI 30 with at least one of the following: heart failure with preserved ejection fraction (HFpEF), hypertension, or chronic kidney disease (CKD) BMI 27 with a history of pre-diabetes, myocardial infarction, stroke, or peripheral artery disease (PAD) The program covers the following GLP-1 receptor agonists: Foundayo (orforglipron) tablet, all dose strengths and formulations Wegovy (semaglutide) injections and tablets, all dose strengths and formulations Zepbound (tirzepatide) injections, only when prescribed as the KwikPen (single-dose vials and other single-dose pen formats are excluded) All prescriptions require prior authorization through Humana, which oversees clinical review to ensure adherence to the program's strict medical-necessity guidelines

When high levels of sodium are detected by the macula densa, the tubuloglomerular feedback mechanism is inhibited, causing constriction of the afferent arteriole, which decreases glomerular capillary hydrostatic pressure and reduces the glomerular filtration rate
Room temperature water goes down easier than cold when nauseated
We're all different and it's okay
In 2021, roughly half of all adults worldwide one billion men and 1.11 billion women over the age of 25 were overweight or obese